StockData
ImmunityBio, Inc. logo

ImmunityBio, Inc. (IBRX) stock

IBRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 8/30
$8.29−0.45 (-5.15%)

Close on Oct 30, 2026Market cap $8.79BP/E –Yield –

Earnings

ImmunityBio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 4, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q1 FY2026
$44.21M
+167.9% on a year earlier
EPS, Q1 FY2026
-$0.62
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of ImmunityBio's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 4, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 4, 2026before the open–––Release
Q1 FY2026ended Mar 31, 2026May 7, 2026before the open$44.21M+167.9%-$0.62Release
Q4 FY2025ended Dec 31, 2025Jan 15, 2026before the open$38.30M––Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025after the close–––Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025before the open$26.40M–-$0.10Release
Q1 FY2025ended Mar 31, 2025Apr 15, 2025before the open$16.50M––Release
Q4 FY2024ended Dec 31, 2024Mar 3, 2025before the open–––Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024before the open–––Release
Q4 FY2022ended Dec 31, 2022Feb 14, 2023after the close–––Filing
Q3 FY2022ended Sep 30, 2022Dec 12, 2022before the open–––Release
Q2 FY2021ended Jun 30, 2021Sep 13, 2021before the open–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

ImmunityBio has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When ImmunityBio puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases ImmunityBio filed with the SEC as exhibits to Form 8-K or 6-K

  1. FDA Expands ANKTIVA ® Approval
    Update
  2. ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million,
    Results
  3. ImmunityBio Receives United Arab Emirates (UAE) Marketing
    Update
  4. ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to
    Update
  5. ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue
    Results
  6. ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year
    Results
  7. ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
    Update
  8. ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of
    Update
  9. ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded
    Results
  10. ImmunityBio Receives Authorization from the European Commission
    News
  11. ImmunityBio Reports Continued Execution and Sales
    Results
  12. Saudi FDA Grants Accelerated Approval to ImmunityBio’s
    News
  13. Saudi FDA Grants Accelerated Approval to ImmunityBio’s
    News
  14. ImmunityBio Receives Conditional Marketing Authorization
    News
  15. Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth
    Results